A soft X-Ray Phase-Based Microscope for Biomedical Applications

用于生物医学应用的软 X 射线相位显微镜

基本信息

  • 批准号:
    10376333
  • 负责人:
  • 金额:
    $ 52.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-05-15 至 2024-01-31
  • 项目状态:
    已结题

项目摘要

Abstract Biomedical images are typically obtained utilizing optical light or X-rays. Optical light is suitable for thin tissue slices, but not suitable for obtaining quality 3D images of thick tissue. Tissue specimens up to millimeter in thickness provide information about structure, different cell types and their relationships. One of the problems with optical imaging in thick tissue is the scattering of the optical light. X-rays can penetrate thick tissue, but the currently commercially available X-ray microscope imaging systems, such as the XRadia and Rigaku systems, are not optimal for soft tissue imaging. For the Xradia Versa, the lowest energy X-ray spectrum is 30 kVp, which is too high for soft tissue, while in the Xradia Ultra the field of view is only ~60 µm, and 3D imaging requires several hours. In the case of the Rigaku system, absorption contrast is too low even at low energies. We propose to deliver an intensity-modulation phase-based soft X-ray microscope for non-destructive synchrotron-quality imaging of intact biological samples with the following features:  3D, quantitative and multimodal (phase, attenuation, scatter) images  Acquisition times more than 10 times shorter than in XRadia systems  Resolution of hundreds of nm, same as visible light microscopes  Field of view from 5 mm x 5 mm to 1 mm x 1 mm, resolution from 2 µm to less than 0.5 µm  High-contrast images of cell composition  Imaging tissue/cells in their native hydrated state, with no staining and other disrupting preparation procedures  Implementing two low energy X-ray sources: 5.4 keV and 8 keV. The user can switch back and forth between the two options, as well as adjust the resolution dynamically This will be realized by combining intensity-modulation X-ray phase-based imaging (IM XPBI) method with two innovations such as cycloidal CT acquisition and lab-based ptychography. The microscope will be installed at Memorial Sloan Kettering Cancer Center and validated with a database of existing tissue samples. The 3D histology results from the proposed microscope will be compared to histology results from conventional imaging modalities to determine efficacy. Tests will also be carried out to study cancer- associated cells in blood, such as circulating tumor cells and giant cancer-associated macrophage-like cells discovered by Creatv MicroTech. Possibility to obtain high- resolution high-contrast 3D images of cells in their native state will enhance our biomedical research and clinical utility to cancer. This novel technology will be helpful for basic, pre-clinical and clinical studies related to many health conditions, such as cancer, osteoporosis, arthritis, cardiovascular disease and will assist with understanding of how these diseases progress and how they can be treated.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joseph David Ferrara其他文献

Joseph David Ferrara的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joseph David Ferrara', 18)}}的其他基金

A soft X-Ray Phase-Based Microscope for Biomedical Applications
用于生物医学应用的软 X 射线相位显微镜
  • 批准号:
    10160910
  • 财政年份:
    2020
  • 资助金额:
    $ 52.57万
  • 项目类别:
A soft X-Ray Phase-Based Microscope for Biomedical Applications
用于生物医学应用的软 X 射线相位显微镜
  • 批准号:
    10606563
  • 财政年份:
    2020
  • 资助金额:
    $ 52.57万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
  • 批准号:
    10068495
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
  • 批准号:
    24K19850
  • 财政年份:
    2024
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
  • 批准号:
    489316
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
  • 批准号:
    23K14987
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 52.57万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了